Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Crinetics Pharmaceuticals (CRNX) Leases (2019 - 2025)

Crinetics Pharmaceuticals has reported Leases over the past 7 years, most recently at $40.5 million for Q4 2025.

  • Quarterly results put Leases at $40.5 million for Q4 2025, down 6.93% from a year ago — trailing twelve months through Dec 2025 was $40.5 million (down 6.93% YoY), and the annual figure for FY2025 was $40.5 million, down 6.93%.
  • Leases for Q4 2025 was $40.5 million at Crinetics Pharmaceuticals, down from $41.1 million in the prior quarter.
  • Over the last five years, Leases for CRNX hit a ceiling of $48.0 million in Q3 2023 and a floor of $1.3 million in Q2 2023.
  • Median Leases over the past 5 years was $21.3 million (2021), compared with a mean of $22.8 million.
  • Biggest five-year swings in Leases: dropped 26.16% in 2023 and later skyrocketed 3492.18% in 2024.
  • Crinetics Pharmaceuticals' Leases stood at $1.9 million in 2021, then dropped by 21.46% to $1.5 million in 2022, then surged by 3032.5% to $46.5 million in 2023, then fell by 6.54% to $43.5 million in 2024, then fell by 6.93% to $40.5 million in 2025.
  • The last three reported values for Leases were $40.5 million (Q4 2025), $41.1 million (Q3 2025), and $41.9 million (Q2 2025) per Business Quant data.